Exceptions Or Alternatives to Labeling Requirements for Products Held by the Strategic National Stockpile

ICR 201407-0910-011

OMB: 0910-0614

Federal Form Document

Forms and Documents
Document
Name
Status
Supporting Statement A
2014-07-14
ICR Details
0910-0614 201407-0910-011
Historical Active 201104-0910-013
HHS/FDA CBER
Exceptions Or Alternatives to Labeling Requirements for Products Held by the Strategic National Stockpile
Extension without change of a currently approved collection   No
Regular
Approved without change 08/21/2014
Retrieve Notice of Action (NOA) 07/22/2014
  Inventory as of this Action Requested Previously Approved
08/31/2017 36 Months From Approved 08/31/2014
2 0 3
32 0 56
0 0 0

The appropriate FDA Center Director may grant an exception or alternative to certain FDA labeling requirements if compliance with the requirements could adversely affect the safety, effectiveness, or availability of products that are or will be included in the SNS. An exception or alternative granted under this rule may include conditions or safeguards so that the labeling for such products includes appropriate information necessary for the safe and effective use of the product given the product's anticipated circumstances of use. This facilitates the safety, effectiveness, and availability of appropriate medical countermeasures in the event of a public health emergency. If the request is granted, the manufacturer may need to report to FDA any resulting changes to the new drug application (NDA), biologics license application (BLA), premarket approval application (PMA), or premarket notification (510(k)) in effect, if any. The submission and grant of a request for an exception or alternative to the labeling requirements may be used to satisfy certain reporting obligations relating to changes to product applications under § 314.70 (21 CFR 314.70) (human drugs), § 601.12 (21 CFR 601.12) (biological drugs), § 814.39 (21 CFR 814.39) (medical devices subject to premarket approval), or § 807.81 (21 CFR 807.81) (medical devices subject to premarket notification submission (510(k) clearance) requirements).

PL: Pub.L. 107 - 188 121 Name of Law: PHS and Bioterrorism Preparedness and Response Act
   US Code: 42 USC 247d-6b Name of Law: PHS Act
   US Code: 21 USC 352 Name of Law: FFDCA
  
None

Not associated with rulemaking

  79 FR 9219 02/18/2014
79 FR 41582 07/16/2014
Yes

  Total Approved Previously Approved Change Due to New Statute Change Due to Agency Discretion Change Due to Adjustment in Estimate Change Due to Potential Violation of the PRA
Annual Number of Responses 2 3 0 -1 0 0
Annual Time Burden (Hours) 32 56 0 -24 0 0
Annual Cost Burden (Dollars) 0 0 0 0 0 0
No
Yes
Miscellaneous Actions
The estimated total annual burden for this information collection in 2011 was 56 hours. The current decrease in total annual burden to 32 hours is attributed to the decrease in total annual responses (1) for a response for an exception or alternative to certain labeling requiremetns submitted to FDA.

$2,800
No
No
No
No
No
Uncollected
Ila Mizrachi 301 796-7726 [email protected]

  No

On behalf of this Federal agency, I certify that the collection of information encompassed by this request complies with 5 CFR 1320.9 and the related provisions of 5 CFR 1320.8(b)(3).
The following is a summary of the topics, regarding the proposed collection of information, that the certification covers:
 
 
 
 
 
 
 
    (i) Why the information is being collected;
    (ii) Use of information;
    (iii) Burden estimate;
    (iv) Nature of response (voluntary, required for a benefit, or mandatory);
    (v) Nature and extent of confidentiality; and
    (vi) Need to display currently valid OMB control number;
 
 
 
If you are unable to certify compliance with any of these provisions, identify the item by leaving the box unchecked and explain the reason in the Supporting Statement.
07/22/2014


© 2024 OMB.report | Privacy Policy